A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Alkermes Plc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 260,785 shares of ALKS stock, worth $7.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260,785
Previous 242,638 7.48%
Holding current value
$7.28 Million
Previous $5.85 Million 24.83%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.01 - $28.55 $417,562 - $518,096
18,147 Added 7.48%
260,785 $7.3 Million
Q2 2024

Aug 14, 2024

BUY
$23.21 - $27.24 $677,755 - $795,435
29,201 Added 13.68%
242,638 $5.85 Million
Q1 2024

May 09, 2024

BUY
$26.4 - $32.56 $4.05 Million - $5 Million
153,495 Added 256.07%
213,437 $5.78 Million
Q4 2023

Feb 06, 2024

BUY
$23.37 - $28.68 $13,367 - $16,404
572 Added 0.96%
59,942 $1.66 Million
Q3 2023

Nov 13, 2023

SELL
$27.17 - $31.97 $1.86 Million - $2.19 Million
-68,544 Reduced 53.59%
59,370 $1.66 Million
Q2 2023

Dec 12, 2023

BUY
$28.34 - $33.63 $1.94 Million - $2.31 Million
68,544 Added 115.45%
127,914 $4 Million
Q2 2023

Aug 08, 2023

SELL
$28.34 - $33.63 $112,311 - $133,275
-3,963 Reduced 3.01%
127,914 $4 Million
Q1 2023

Dec 12, 2023

BUY
$25.31 - $29.02 $1.74 Million - $1.99 Million
68,556 Added 115.47%
127,926 $3.61 Million
Q1 2023

May 01, 2023

BUY
$25.31 - $29.02 $11,364 - $13,029
449 Added 0.34%
131,877 $3.72 Million
Q4 2022

Feb 03, 2023

BUY
$21.94 - $26.24 $612,718 - $732,804
27,927 Added 26.98%
131,428 $3.43 Million
Q3 2022

Nov 08, 2022

BUY
$22.0 - $31.87 $135,872 - $196,829
6,176 Added 6.35%
103,501 $2.31 Million
Q2 2022

Aug 09, 2022

BUY
$26.4 - $30.54 $334,752 - $387,247
12,680 Added 14.98%
97,325 $2.9 Million
Q1 2022

May 05, 2022

SELL
$23.07 - $27.99 $86,166 - $104,542
-3,735 Reduced 4.23%
84,645 $2.23 Million
Q4 2021

Feb 02, 2022

BUY
$21.47 - $32.08 $3,692 - $5,517
172 Added 0.19%
88,380 $2.06 Million
Q3 2021

Oct 26, 2021

SELL
$23.37 - $32.13 $13,905 - $19,117
-595 Reduced 0.67%
88,208 $2.72 Million
Q2 2021

Jul 27, 2021

BUY
$18.78 - $25.15 $95,834 - $128,340
5,103 Added 6.1%
88,803 $2.18 Million
Q1 2021

Apr 27, 2021

BUY
$18.21 - $23.2 $244,268 - $311,204
13,414 Added 19.08%
83,700 $1.56 Million
Q4 2020

Jan 29, 2021

BUY
$15.39 - $22.1 $692 - $994
45 Added 0.06%
70,286 $1.4 Million
Q3 2020

Nov 10, 2020

SELL
$16.16 - $20.66 $269,484 - $344,526
-16,676 Reduced 19.19%
70,241 $1.16 Million
Q1 2020

Apr 28, 2020

SELL
$13.06 - $21.24 $1,214 - $1,975
-93 Reduced 0.11%
86,917 $1.25 Million
Q4 2019

Feb 12, 2020

SELL
$17.29 - $21.74 $309,300 - $388,906
-17,889 Reduced 17.05%
87,010 $1.78 Million
Q3 2019

Oct 29, 2019

BUY
$19.51 - $24.28 $18,885 - $23,503
968 Added 0.93%
104,899 $2.05 Million
Q2 2019

Jul 30, 2019

BUY
$21.47 - $37.33 $322,050 - $559,950
15,000 Added 16.87%
103,931 $2.34 Million
Q1 2019

Apr 22, 2019

BUY
$28.4 - $36.49 $101,586 - $130,524
3,577 Added 4.19%
88,931 $3.25 Million
Q4 2018

Jan 25, 2019

BUY
$27.94 - $44.61 $640,748 - $1.02 Million
22,933 Added 36.74%
85,354 $2.52 Million
Q3 2018

Oct 24, 2018

SELL
$38.6 - $46.12 $771,073 - $921,293
-19,976 Reduced 24.24%
62,421 $2.65 Million
Q2 2018

Jul 09, 2018

SELL
$40.56 - $51.36 $374,368 - $474,052
-9,230 Reduced 10.07%
82,397 $3.39 Million
Q1 2018

May 11, 2018

SELL
$53.61 - $67.26 $6.68 Million - $8.39 Million
-124,693 Reduced 57.64%
91,627 $5.31 Million
Q1 2018

Apr 19, 2018

BUY
$53.61 - $67.26 $5.72 Million - $7.18 Million
106,733 Added 97.4%
216,320 $12.5 Million
Q4 2017

Jan 24, 2018

SELL
$47.69 - $55.39 $26,563 - $30,852
-557 Reduced 0.51%
109,587 $6 Million
Q3 2017

Oct 17, 2017

BUY
$49.16 - $54.45 $5.41 Million - $6 Million
110,144
110,144 $5.6 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.58B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.